Trial Profile
Phase I trial of KB 001 for prevention of P. aeruginosa infections in mechanically ventilated patients (USA trial)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 22 Sep 2017
Price :
$35
*
At a glance
- Drugs KB 001-A (Primary)
- Indications Pseudomonal infections
- Focus Adverse reactions
- Sponsors Sanofi Pasteur
- 07 Aug 2017 According to a Humanigen media release, KaloBios Pharmaceuticals changed its name to Humanigen.
- 30 Apr 2013 New trial record